Lumosa Therapeutics Co., Ltd. (TPEX:6535)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
142.50
-6.00 (-4.04%)
Apr 2, 2026, 1:30 PM CST
Market Cap23.87B -37.9%
Revenue (ttm)35.83M -8.5%
Net Income-340.54M
EPS-2.05
Shares Out167.49M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume134,460
Average Volume171,462
Open148.50
Previous Close148.50
Day's Range141.50 - 149.50
52-Week Range122.00 - 329.50
Beta0.22
RSI38.57
Earnings DateMay 11, 2026

About Lumosa Therapeutics

Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops drugs for neurological and oncological diseases in Taiwan and the rest of Asia. The company offers Naldebain (LT-1001), an analgesic injection for postoperative pain. It also develops LT3001, which has completed Phase 2b clinical trials for the treatment of acute ischemic stroke; LT6001, which is in pre-clinical trials for the treatment of neurological disorders; and CS028, which is in the pre-clinical stage for the treatment of solid tumors. In addition, the compa... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 39
Stock Exchange Taipei Exchange
Ticker Symbol 6535
Full Company Profile

Financial Performance

In 2025, Lumosa Therapeutics's revenue was 35.83 million, a decrease of -8.49% compared to the previous year's 39.15 million. Losses were -340.54 million, -19.83% less than in 2024.

Financial Statements